SynthesisJournal of the European Academy of Dermatology and Venereology : JEADV2022
The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes.
Synthesis in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.JAMA dermatology · 2025Trial
- [Vitiligo in Germany : A claims data analysis on prevalence, comorbidity, and treatment patterns].Dermatologie (Heidelberg, Germany) · 2026Article
- Current Management and Emerging Therapies for Pediatric Vitiligo: A Narrative Review.Paediatric drugs · 2026Review
- Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.The Journal of international medical research · 2026Review
- Health-Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan.The Journal of dermatology · 2026Article
- Bioinformatics analysis reveals the characteristics of immune microenvironment in major depressive disorder and vitiligo.PloS one · 2026Article
- Vitiligo.Nature reviews. Disease primers · 2025Review
- Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.Dermatology and therapy · 2025Article
- The Impact of Vitiligo on Patients' Quality of Life: Retrospective Observational Study.International journal of dermatology · 2025Article
- Vitiligo.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- Canadian Consensus Guidelines for the Management of Vitiligo.Dermatology and therapy · 2025Article
- Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis.Dermatology and therapy · 2025Article
- Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database.The Journal of dermatology · 2025Article
- [Vitiligo-update on pathogenesis, diagnostics and therapy].Dermatologie (Heidelberg, Germany) · 2025Review
- Validation of the vitiligo-specific quality-of-life instrument (VitiQoL) for the Turkish language: the VitiQoL-TR study.Archives of dermatological research · 2025Article
- Impact on quality of life, health care access, and health care utilization of individuals with vitiligo: an analysis of the All of Us research program.Archives of dermatological research · 2024Article
- Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.EClinicalMedicine · 2024Article
- Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients.Dermatology and therapy · 2024Article
- Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location.Dermatology and therapy · 2024Article
- [Quality of life, disease burden and healthcare need of patients with vitiligo].Dermatologie (Heidelberg, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite historical mischaracterization as a cosmetic condition, patients with the autoimmune disorder vitiligo experience substantial quality-of-life (QoL) burden. This systematic literature review of peer-reviewed observational and interventional studies describes comprehensive evidence for humanistic burden in patients with vitiligo. PubMed, EMBASE, Scopus and the Cochrane databases were searched through February 10, 2021, to qualitatively assess QoL in vitiligo. Two independent reviewers assessed articles for inclusion and extracted data for qualitative synthesis. A total of 130 included studies were published between 1996 and 2021. Geographical regions with the most studies were Europe (32.3%) and the Middle East (26.9%). Dermatology-specific instruments, including the Dermatology Life Quality Index (DLQI; 80 studies) and its variants for children (CDLQI; 10 studies) and families (FDLQI; 4 studies), as well as Skindex instruments (Skindex-29, 15 studies; Skindex-16, 4 studies), were most commonly used to measure humanistic burden. Vitiligo-specific instruments, including the Vitiligo-specific QoL (VitiQoL; 11 studies) instrument and 22-item Vitiligo Impact Scale (VIS-22; 4 studies), were administered in fewer studies. Among studies that reported total scores for the overall population, a majority revealed moderate or worse effects of vitiligo on patient QoL (DLQI, 35/54 studies; Skindex, 8/8 studies; VitiQoL, 6/6 studies; VIS-22, 3/3 studies). Vitiligo also had a significant impact on the QoL of families and caregivers; 4/4 studies reporting FDLQI scores indicated moderate or worse effects on QoL. In general, treatment significantly (P < 0.05) improved QoL, but there were no trends for types or duration of treatment. Among studies that reported factors significantly (P ≤ 0.05) associated with reduced QoL, female sex and visible lesions and/or lesions in sensitive areas were most common. In summary, vitiligo has clinically meaningful effects on the QoL of patients, highlighting that greater attention should be dedicated to QoL decrement awareness and improvement in patients with vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.